Central venous access devices in haemophilia

Haemophilia

Volumn 10, Issue 2, 2004, Pages 134-146

  Valentino, Leonard A ^a   Ewenstein, B ^b   Navickis, R J ^c   Wilkes, M M ^c  

^a Rush Children's Hospital and Rush University Medical Center   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c Hygeia Associates   (United States)

Author keywords

Haemophilia; Infection; Meta analysis; Removal; Thrombosis; Venous access devices

Indexed keywords

BLOOD CLOTTING FACTOR;

CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEVICE; DISEASE SEVERITY; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOSIS; VASCULAR ACCESS;

EID: 1542330950     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00840.x     Document Type: Review

References (97)

1. Fontes B, Ferreira Filho AA, Carelli CR, Fontes W, Birolini D, Bevilacqua RJ. Percutaneous catheterization of the subclavian vein in hemophiliac patients: report of 47 cases. Int Surg 1992; 77: 118-21.
2. Girvan DP, de Veber LL, Inwood MJ, Clegg EA. Subcutaneous infusion ports in the pediatric patient with hemophilia. J Pediatr Surg 1994; 29: 1220-3.
3. Lilleyman JS. Domiciliary desensitization therapy for young boys with haemophilia and factor VIII inhibitors. Br J Haematol 1994; 86: 433-5.
4. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
5. Vidler V. Use of Port-a-Caths in the management of paediatric haemophilia. Prof Nurse 1994; 10: 48-50.
6. Goldsmith JC, Miller R, Boody B, Atkinson J. Central venous catheter related complications in children with hemophilia. Blood 1995; 86: 872a.
7. Hilgartner MW, Kleinert D. Morbidity of central lines in patients with coagulation deficiencies. Pediatr Res 1995; 37: 158A.
8. Liesner RJ, Vora AJ, Hann IM, Lilleymann JS. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995; 91: 203-7.
9. Blanchette VS, Al-Musa A, Stain AM, Filler RM, Ingram J. Central venous access catheters in children with haemophilia. Blood Coagul Fibrinolysis 1996; 7 (Suppl. 1): S39-44.
10. Perkins JL, Johnson VA, Osip JM et al. The use of implantable venous access devices (IVADs) in children with hemophilia. J Pediatr Hematol Oncol 1997; 19: 339-44.
11. Ragni MV, Hord JD, Blatt J. Central venous catheter infection in hemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. Haemophilia 1997; 3: 90-5.
12. Warrier I, Baird-Cox K, Lusher J. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia 1997; 3: 194-8.
13. Geraghty S, Kleinert D. Use and morbidity of venous access devices in patients with hemophilia. J Intraven Nurs 1998; 21: 70-5.
14. Ljung R, van den Berg M, Petrini P et al. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998; 87: 1051-4.
15. Medeiros D, Miller KL, Rollins NK, Buchanan GR. Contrast venography in young haemophiliacs with implantable central venous access devices. Haemophilia 1998; 4: 10-5.
16. Miller K, Buchanan GR, Zappa S et al. Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998; 132: 934-8.
17. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102: 1224-8.
18. Blanchette VS, Al-Trabolsi H, Stain AM et al. High risk of central venous line-associated thrombosis in boys with hemophilia. Blood 1999; 94: 234a.
19. Kreuz W, Ettingshausen CE, Funk M, Pons S, Schmidt H, Kornhuber B. Gelenkveränderungen bei hämophilen Kindern dutch frühzeitge Prophylaxe. Orthopäde 1999; 28: 341-6.
20. Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe haemophilia. Br J Haematol 1999; 104: 461-4.
21. Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003; 9: 50-6.
22. Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588-92.
23. van den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia - a review. Haemophilia 1998; 4: 418-20.
24. Stram DO. Meta-analysis of published data using a linear mixed-effects model. Biometrics 1996; 52: 536-44.
25. Rabe-Hesketh S, Skrondal A, Pickles A. Reliable estimation of generalized linear mixed models using adaptive quadrature. Stata J 2002; 2: 1-21.
26. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51: 1-29.
27. Joshi R, Barrett AJ, Wastell C, Gibberd FB. Use of a Hickman catheter for permanent venous access in a patient with severe haemophilia. Clin Lab Haematol 1982; 4: 319-21.
28. Miser AW, Roach JE, Harmel RP Jr, Sayers MP, Miser JS. Insertion of a central venous catheter for long-term venous access in a child with severe hemophilia and recurrent intracranial hemorrhage. Clin Pediatr (Phila) 1984; 23: 589.
29. McWhirter WR, Gray L. Indwelling intravenous catheter in a young haemophiliac. Lancet 1988; 2: 99-100.
30. Hockenberry MJ, Schultz WH, Bennett B, Bryant R, Falletta JM. Experience with minimal complications in implanted catheters in children. Am J Pediatr Hematol Oncol 1989; 11: 295-9.
31. Schultz WH, Ware R, Filston HC, Kinney TR. Prolonged use of an implantable central venous access system in a child with severe hemophilia. J Pediatr 1989; 114: 100-1.
32. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6: 66-70.
33. Damiano ML, Hutter JJ Jr. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000; 6: 526-32.
34. Feldman BM, Rivard G, Israels S et al. Preliminary results from the Canadian Hemophilia Prophylaxis Trial. Haemophilia 2000; 6: 272.
35. Li CH, Ou Y, Lee AC, So KT. Septic arthritis in hemophilia with central venous catheter: a case report. Pediatr Hematol Oncol 2000; 17: 187-9.
36. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000; 6: 619-24.
37. Manco-Johnson M, Nuss R, Abshire T, Richardson L, Shapiro A, Valentino L. Port infections in children with haemophilia. Haemophilia 2000; 6: 275.
38. McMahon C, Smith J, Khair K, Liesner R, Hann IM, Smith OP. Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome. Br J Haematol 2000; 110: 461-8.
39. Rothschild C, Merckx J, Clairicia M, Dazet D, Torchet MF, Pertuiset N. Experience with implantable venous access devices in haemophilic children treated intensively: a low rate of complications. Haemophilia 2000; 6: 276.
40. Hothi DK, Kelsall W, Baglin T, Williams DM. Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters. Haemophilia 2001; 7: 507-10.
41. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-31.
42. Mannucci PM, Mendolicchio L, Gringeri A. Use of prophylaxis to prevent complications of hemophilia. Adv Exp Med Biol 2001; 489: 59-64.
43. Morado M, Jimenez-Yuste V, Villar A et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001; 7: 551-6.
44. Santagostino E, Gringeri A, Muca-Perja M, Berardinelli L, Mannucci P. Prospective evaluation of permanent venous accesses in children with hemophilia: safety and feasibility of port-a-cath and arterio-venous fistula. Thromb Haemost 2001; 85: OC1745.
45. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
46. Centers for Disease Control and Prevention (CDC). Report on the Universal Data Collection Program (UDC), 2002. www.cdc.gov/ncidod/dastlr/hematology/HDBpubs.htm
47. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
48. Ettingshausen CE, Kurnik K, Schobess R et al. Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Blood 2002; 99: 1499-500.
49. Girisch M, Rauch R, Lischetzki G, Ries M, Klinge J. Central venous catheters (Port-A-Cath) for treatment of children with haemophilia. Haemophilia 2002; 8: 488.
50. Panicker J, Warrier I, Lusher J. The impact of prophylaxis on children with severe haemophilia. Haemophilia 2002; 8: 489-90.
51. Tusell J, Cid AR, Sosa R, Villar A, Lucia JF. Haemophilia prophylactic treatment in Spain. Haemophilia 2002; 8: 729-32.
52. Tusell J, Villar A, Lopez-Fernandez F et al. Ports in children with congenital coagulopathies: Spanish registry. Haemophilia 2002; 8: 488.
53. Wiegand G, Rauch R, Effenberger W, Hofbecks M. Cardiomyopathy following port-implantation for immune tolerance therapy. Haemophilia 2002; 8: 490.
54. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
55. van Dijk K, van Den Berg HM, van der Bom JG. Complications of port-a-cath (PAC) in children with severe haemophilia. Haemophilia 2002; 8: 488.
56. Ljung R, Petrini P, Lindgren AK, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81: 918-20.
57. Ljung R, Lindgren AK, Tengborn L, Petrini P. The feasibility of long-term venous access in children with hemophilia. Semin Hematol 1994; 31 (Suppl. 2): 16-8.
58. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S. A prophylactic program in the United States: experience and issues. Semin Hematol 1994; 31: 10-2.
59. Zappa SC, Johnson AG, Cochran CJ, Sanders JM, Buchanan GR. Implantable intravenous access devices in children with hemophilia. Arch Pediatr Adolesc Med 1994; 148: 327-30.
60. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
61. Ljung R, van den Berg HM, Petrini P, Tengborn L, Scheibel E, Effenberger W. Experience with the Port-A-Cath in children with haemophilia: a multicentre study. Haemophilia 1996; 2 (Suppl. 1): 17.
62. Petrini P, Klementz G. Clinical experience of early prophylaxis in young haemophiliacs. Haemophilia 1996; 2 (Suppl. 1): 63.
63. Blanchette VS, Al-Musa A, Stain AM, Ingram J, Fille RM. Central venous access devices in children with hemophilia: an update. Blood Coagul Fibrinolysis 1997; 8 (Suppl. 1): S11-4.
64. Collins PW, Khair KS, Liesner R, Hann IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997; 99: 206-8.
65. Liesner RJ. Prophylaxis in haemophilic children. Blood Coagul Fibrinolysis 1997; 8 (Suppl. 1): S7-10.
66. Gringeri A, Bianchi A, Group ES. Evaluation study on prophylaxis: a randomized Italian trial (ESPRIT): two-year report. Thromb Haemost 1999; 82 (Suppl.): 1487.
67. Harrington C, Pollard D, Yee TT, Brown SA, Lee CA. Experience of home treatment training for children with severe haemophilia and their parents. Haemophilia 2000; 6: 274.
68. Morado M, Villar A, Jimenez Yuste V et al. Complication of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2000; 6: 275-6.
69. Santagostino E, Gringeri A, Muca-Perja M, Coluccia P, Berardinelli L, Mannucci P. Study on long-term safety of Port-a-Cath use in children with haemophilia: which alternatives? Haemophilia 2000; 6: 277.
70. Shapiro AD, Donfield SM. Infectious complications of central venous access devices (CVAD) in children with haemophilia. Haemophilia 2000; 6: 278.
71. Yee TT, Beeton K, Harrington C, Miners A, Brown SA, Lee C. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2000; 6: 278.
72. Panicker J, Warrier I, Lusher JM, Thomas R. The impact of prophylaxis on children with severe hemophilia. Blood 2001; 98: 531a.
73. Lucia JF, Aznar JA, Sosa R, Villar A, Tusell J. Haemophilia prophylactic treatment in Spain. Haemophilia 2002; 8: 489.
74. van den Berg HM, Fischer K, van der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002; 8 (Suppl. 2): 43-6.
75. Vora A, Lilleyman JS. Vascular access in young hemophiliacs: use of indwelling central venous catheters. Int J Ped Hem Onc 1994; 1: 521-7.
76. Pearson ML. Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. The Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996; 24: 262-77.
77. Gleason-Morgan D, Church JA, Bagnall-Reeb H, Atkinson J. Complications of central venous catheters in pediatric patients with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991; 10: 11-4.
78. Ingram J, Weitzman S, Greenberg ML, Parkin P, Filler R. Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters and subcutaneous ports. Am J Pediatr Hematol Oncol 1991; 13: 130-6.
79. Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol 1995; 17: 342-5.
80. Rubie H, Juricic M, Claeyssens S et al. Morbidity using subcutaneous ports and efficacy of vancomycin flushing in cancer. Arch Dis Child 1995; 72: 325-9.
81. Daghistani D, Horn M, Rodriguez Z, Schoenike S, Toledano S. Prevention of indwelling central venous catheter sepsis. Med Pediatr Oncol 1996; 26: 405-8.
82. Deerojanawong J, Sawyer SM, Fink AM, Stokes KB, Robertson CF. Totally implantable venous access devices in children with cystic fibrosis: incidence and type of complications. Thorax 1998; 53: 285-9.
83. Aitken ML, Tonelli MR. Complications of indwelling catheters in cystic fibrosis: a 10-year review. Chest 2000; 118: 1598-602.
84. Whitman ED. Complications associated with the use of central venous access devices. Curr Probl Surg 1996; 33: 309-78.
85. Groeger JS, Lucas AB, Thaler HT et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119: 1168-74.
86. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. J Intraven Nurs 2001; 24: 180-205.
87. Decker MD, Edwards KM. Central venous catheter infections. Pediatr Clin North Am 1988; 35: 579-612.
88. Pegues D, Axelrod P, McClarren C et al. Comparison of infections in Hickman and implanted port catheters in adult solid tumor patients. J Surg Oncol 1992; 49: 156-62.
89. Mirro J Jr, Rao BN, Kumar M et al. A comparison of placement techniques and complications of externalized catheters and implantable port use in children with cancer. J Pediatr Surg 1990; 25: 120-4.
90. Mirro J Jr, Rao BN, Stokes DC et al. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. J Clin Oncol 1989; 7: 214-22.
91. O'Keefe SJ, Burnes JU, Thompson RL. Recurrent sepsis in home parenteral nutrition patients: an analysis of risk factors. JPEN J Parenter Enteral Nutr 1994; 18: 256-63.
92. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol 2003; 10: 369-74.
93. Ragni M. Infectious and thrombotic complications of central venous catheters in hemophilia patients. Home Healthcare Consultant 1998. www.mmhc.com/hhcc/articles/HHCC9809/ragni.html
94. Buchanan GR, Miller K, Zajac JL. Upper venous system thrombosis in haemophilia patients with long-term implantable central venous catheters. Haemophilia 2000; 6: 271.
95. Journeycake JM, Buchanan GR. Catheter-related thrombosis in children with hemophilia A. Blood 2002; 99: 1500.
96. Matsuyama K, Ushijima K, Kano T, Tsuchiya H. Intraoperative use of plasma-derived activated factor VII (F VII a) in a hemophilia A patient with inhibitors. Masui 1996; 45: 235-8.
97. Smith OP, Hann IM. rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br J Haematol 1996; 92: 1002-4.